Our Alzheimer's Disease Research Center (ADRC) has a major commitment to investigations of aging and age-associated diseases, including illnesses that occur in subjects with Alzheimer's disease (AD) and in older individuals with Down's Syndrome (DS). We believe that genetic factors, abnormalities of protein processing, and age play important roles in the cognitive/memory impairments and in the brain pathology that occur in these individuals. The interface between biological processes and clinical issues (i.e., subtypes of disease, risk and prognostic factors, and relationship of clinical phenotype to brain pathology) are addressed in Cores B and C. At a basic science level, we need more information about the mechanisms that lead to: selective vulnerability of specific neurons; cytoskeletal abnormalities in these cells; the formation of senile plaques; the pathways by which disease spreads; and the occurrence of death of neurons. Moreover, no therapies are available for these disorders. Building upon Core support, Projects 1-6 address some of these issues, focusing on clinical-pathological correlations (Project 2,3,5), the problems of selective vulnerability and the spatial/temporal evolution of pathology (Projects 1,3,4), and molecular mechanisms that lead to neuronal abnormalities characteristic of aging (Projects 1,2), AD (Projects 1,4,5), and DS (Projects 1,3). We believe that these disorders may eventually be amenable to therapeutic approaches, and, in Project 6, we test three biological therapies (i.e., nerve growth factor, peripheral nerve grafts, and neural grafts) designed to influence basal forebrain cholinergic neurons in several animal models. Ultimately, these lines of research should provide new insights into the natural history of the disease, predictors of prognosis, mechanisms of cellular pathology, and, possibly, new approaches to treatment. Finally, our ADRC is committed to the training of young physicians/scientists who represent our best hope for eventually being able to deal with age-associated disorders, such as AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-10
Application #
3104834
Study Section
Aging Review Committee (AGE)
Project Start
1984-09-28
Project End
1994-03-31
Budget Start
1992-04-13
Budget End
1993-03-31
Support Year
10
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Fredericks, Carolyn A; Sturm, Virginia E; Brown, Jesse A et al. (2018) Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimers Dement (Amst) 10:471-479
Seddighi, Sahba; Varma, Vijay R; An, Yang et al. (2018) SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. J Alzheimers Dis 61:401-414
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
van Bergen, Jiri M G; Li, Xu; Quevenco, Frances C et al. (2018) Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiol Aging 64:68-75
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211

Showing the most recent 10 out of 830 publications